ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Xiao Dong Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-0917-5867; OpenAlex author ID A5101447194. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2024: 1 paper

Papers 1

PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer. Last author DOI 10.1016/j.bbadis.2024.167236 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hong He · 1 shared paper, 2024 · strength 0.20
- Paper PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic ca… DOI 10.1016/j.bbadis.2024.167236 ↗
Kai Wang · 1 shared paper, 2024 · strength 0.20
- Paper PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic ca… DOI 10.1016/j.bbadis.2024.167236 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.